| Literature DB >> 33437521 |
Karen L Reckamp1,2, Jasmine A McQuerry1,3, Isa Mambetsariev1, Rebecca Pharaon1, Susan E Yost1, Jeremy Fricke1, Tamara Mirzapoiazova1, Raju K Pillai4, Ziad Khan1, Marwan Fakih1, Yuan Yuan1, Marianna Koczywas1, Erminia Massarelli1, Prakash Kulkarni1, Sumanta K Pal1, Martin Sattler5,6,7, Andrea Bild1, Ravi Salgia1.
Abstract
The implication of MET alterations in solid tumors and the immune microenvironment remains elusive. Formalin-fixed, paraffin-embedded samples of 21 patients with solid tumors harboring MET alterations were used for immunohistochemical staining. Extracted RNA was analyzed with the NanoString nCounter human PanCancer immune profiling panel (NanoString Technologies, Inc., WA, USA). Patients were diagnosed with lung (n = 10), breast (n = 5), genitourinary (n = 3) or colorectal cancer (n = 3). Eleven had a MET missense mutation, four had an exon 14 splice site mutation and six had MET amplification. CD6, CCL19, CD40LG, XCR1, MAGEA1, ATM and CCL19 genes were significantly differentially expressed in MET-altered cancers. MET alterations may have a role in various solid tumors as potential therapeutic targets and combination therapy candidates with immune checkpoint inhibitors.Entities:
Keywords: MET; NanoString; immune markers; solid tumors; targeted therapy
Year: 2020 PMID： 33437521 PMCID： PMC7787173 DOI： 10.2144/fsoa-2020-0159
Source DB: PubMed Journal: Future Sci OA ISSN： 2056-5623